References

(1) DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2019.

(2) Carney G, Harrison A, Fitzpatrick J. Long-Term Outcome Measures of Repeated Non-Animal Stabilized Hyaluronic Acid (Durolane) Injections in Osteoarthritis: A 6-Year Cohort Study with 623 Consecutive Patients. Open Access Rheumatol. 2021 Sep 18;13:285-292. doi: 10.2147/OARRR.S331562. PMID: 34566438; PMCID: PMC8457651

(3) McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013:2(1);1000108. doi:10.4172/2167-7921.1000108

(4) Leighton R, Åkermark C, Therrien R, et al. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-center, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014;22(1):17-25. doi:10.1016/j.joca.2013.10.009

(5) Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Arthritis Res Ther. 2015;17(1):51. doi:10.1186/s13075-015-0557-x